The weight loss race: Eli Lilly vs. Novo Nordisk

Community consensus from the top comment shows that LLY’s oral weight‑loss pill has generated fewer than 2,000 new scripts per week, two months after launch, while NVO is adding high five‑digit scripts weekly. This massive script gap indicates the market is rejecting LLY’s oral formulation (likely due to efficacy/side‑effect profile vs. NVO’s injectable). If this trend continues, LLY’s near‑term revenue from its obesity pill will miss expectations. Short LLY on the weakness of its pill launch, as the script data points to a failed product rollout that could pressure the stock in the coming quarters. The second commenter notes Mounjaro’s life‑changing effects and believes both companies are eventual winners. LLY’s injectable (Mounjaro) remains strong, and the pill’s low scripts could be temporary due to supply or dosing issues. Price/reimbursement hurdles affect both firms. TICKER: NVO - LONG | confidence: 0.70 | sentiment: +0.70 Speaker: r/stocks community Thesis: The top comment reports NVO is achieving high five‑digit new weekly prescriptions, dramatically outpacing LLY’s oral pill and reinforcing its dominance in the GLP‑1 weight loss market. Strong script momentum signals robust physician and patient adoption, likely translating into accelerating revenue growth. Combined with the second commenter’s view that both companies are “gold mines” once reimbursement expands, NVO is best positioned near‑term. Go long NVO to capture the immediate demand wave evidenced by script data, with a medium‑term catalyst from eventual insurance and social security reimbursement expansion. The thread does not counter NVO’s outlook, but general risks include competition from LLY’s injectable, potential pricing pressure, and regulatory changes. The second commenter sees both companies as eventual winners, implying NVO is not uniquely immune. (Only two trade ideas were extracted because the thread contained only 2 comments with actionable data. No other tickers or directions were explicitly discussed.)